Results 41 to 50 of about 453,940 (280)

Sequence determinants of RNA G‐quadruplex unfolding by Arg‐rich regions

FEBS Letters, EarlyView.
We show that Arg‐rich peptides selectively unfold RNA G‐quadruplexes, but not RNA stem‐loops or DNA/RNA duplexes. This length‐dependent activity is inhibited by acidic residues and is conserved among SR and SR‐related proteins (SRSF1, SRSF3, SRSF9, U1‐70K, and U2AF1).
Naiduwadura Ivon Upekala De Silva, Puspa Kunwar, Md Ibnul Rifat Rahman, Joanna Koryo Kwao, Nathan Lehman, Zihan Zhang, Trenton Paul, Claire Cheng, Nicholas Truex, Hui‐Ting Lee, Jun Zhang   +10 more
wiley   +1 more source

Plasma p‐tau217 concordance with amyloid PET among ethnically diverse older adults

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Commercially available plasma p‐tau217 biomarker tests are not well studied in ethnically diverse samples. METHODS We evaluated associations between ALZPath plasma p‐tau217 and amyloid‐beta positron emission tomography (Aβ‐PET) in Hispanic ...
Breton M. Asken, Jesse C. DeSimone, Wei‐En Wang, Karen N. McFarland, Franchesca Arias, Shellie‐Anne Levy, Jacob Fiala, Idaly Velez‐Uribe, Robin P. Mayrand, Luana Okino Sawada, Christian Freytes, Michael Adeyosoye, Warren W. Barker, Elizabeth A. Crocco, Steven T. DeKosky, Malek Adjouadi, Monica Rosselli, Michael Marsiske, Melissa J. Armstrong, Glenn E. Smith, Rosie Curiel Cid, David A. Loewenstein, David E. Vaillancourt, Ranjan Duara   +23 more
doaj   +1 more source

T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress.
Aladdin H. Shadyab, Andrea Z. LaCroix, Genevieve Matthews, Daniel Bennett, Alexandre A. Shadyab, Donna Tan, Ronald G. Thomas, Jennifer Mason, Alex Lopez, Brianna Askew, Lia Donahue, Stephen Kaplita, Irfan A. Qureshi, Branko Huisa, Howard H. Feldman, for the Alzheimer's Disease Cooperative Study T2 Protect AD Study Group   +15 more
doaj   +1 more source

Semantic Memory Functional MRI and Cognitive Function After Exercise Intervention in Mild Cognitive Impairment [PDF]

, 2013
Mild cognitive impairment (MCI) is associated with early memory loss, Alzheimer\u27s disease (AD) neuropathology, inefficient or ineffective neural processing, and increased risk for AD.
Antuono, Piero, Butts, Alissa, Hanson, Ryan J., Hantke, Nathan, Lyons, Jeri-Annette, Nielson, Kristy A., Smith, J Carson, Verber, Matthew D.   +7 more
core   +2 more sources

Organ‐specific redox imbalances in spinal muscular atrophy mice are partially rescued by SMN antisense oligonucleotides

FEBS Letters, EarlyView.
We identified a systemic, progressive loss of protein S‐glutathionylation—detected by nonreducing western blotting—alongside dysregulation of glutathione‐cycle enzymes in both neuronal and peripheral tissues of Taiwanese SMA mice. These alterations were partially rescued by SMN antisense oligonucleotide therapy, revealing persistent redox imbalance as ...
Sofia Vrettou, Brunhilde Wirth
wiley   +1 more source

Visualization of PS/γ-Secretase Activity in Living Cells

iScience, 2020
Summary: A change in Presenilin (PS)/γ-secretase activity is linked to essential biological events as well as to the progression of many diseases. However, not much is known about how PS/γ-secretase activity is spatiotemporally regulated in cells. One of
Masato Maesako, Nicole M. Sekula, Anna Aristarkhova, Polina Feschenko, Lauren C. Anderson, Oksana Berezovska   +5 more
doaj   +1 more source

Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau)181+231.
Madeline Ally, Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari, Hugo J. Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin, Lindsay A. Farrer, Gyungah R. Jun, Katherine W. Turk, Andrew E. Budson, Maureen K. O'Connor, Rhoda Au, Lee E. Goldstein, Neil W. Kowall, Ronald Killiany, Robert A. Stern, Thor D. Stein, Ann C. McKee, Wei Qiao Qiu, Jesse Mez, Michael L. Alosco   +27 more
doaj   +1 more source

Tau acetylation at K331 has limited impact on tau pathology in vivo

FEBS Letters, EarlyView.
We mapped tau post‐translational modifications in humanized MAPT knock‐in mice and in amyloid‐bearing double knock‐in mice. Acetylation within the repeat domain, particularly around K331, showed modest increases under amyloid pathology. To test functional relevance, we generated MAPTK331Q knock‐in mice.
Shoko Hashimoto, Yukio Matsuba, Mika Takahashi, Takaomi C. Saido   +3 more
wiley   +1 more source

Differential effects of neurodegeneration biomarkers on subclinical cognitive decline

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Introduction Neurodegeneration appears to be the biological mechanism most proximate to cognitive decline in Alzheimer's disease. We test whether t‐tau and alternative biomarkers of neurodegeneration—neurogranin and neurofilament light protein (NFL)—add ...
Andrew P. Merluzzi, Nicholas M. Vogt, Derek Norton, Erin Jonaitis, Lindsay R. Clark, Cynthia M. Carlsson, Sterling C. Johnson, Sanjay Asthana, Kaj Blennow, Henrik Zetterberg, Barbara B. Bendlin   +10 more
doaj   +1 more source

An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy [PDF]

, 2015
BackgroundImaging biomarkers for Alzheimer's disease include medial temporal lobe atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose positron emission ...
Cam Donaldson, Christopher Davison, David Williams, Fahn, Jim Lloyd, John T. O'Brien, Karl Herholz, Kirsty Olsen, Michael J. Firbank, Nicky Barnett, Robert Barber, Roth, Schmidt, Sean J. Colloby   +13 more
core   +1 more source